What is HOOKIPA Pharma?
HOOKIPA Pharma Inc., founded in 2011 and headquartered in New York City, is a clinical-stage biopharmaceutical company. It is pioneering a new class of immunotherapeutics leveraging its proprietary arenavirus platform. This technology is designed to reprogram the body's immune system to combat diseases. The company is actively building a proprietary immuno-oncology pipeline by focusing on virally mediated cancer antigens, self-antigens, and next-generation antigens, aiming to offer innovative treatment options for cancer patients.
How much funding has HOOKIPA Pharma raised?
HOOKIPA Pharma has raised a total of $21.3M across 1 funding round:
Share Placement
$21.3M
Share Placement (2023): $21.3M with participation from Gilead Sciences
Key Investors in HOOKIPA Pharma
Gilead Sciences
Gilead Sciences is a biopharmaceutical company known for its work in developing and commercializing innovative medicines, particularly in areas like HIV, viral hepatitis, and oncology. Their investment in HOOKIPA Pharma suggests a strategic interest in novel immunotherapeutic approaches.
What's next for HOOKIPA Pharma?
The recent major strategic investment signals a pivotal moment for HOOKIPA Pharma, likely enabling the acceleration of its clinical development programs and the expansion of its research initiatives. This backing is expected to fuel the advancement of its arenavirus-based immunotherapies through critical trial phases and towards potential commercialization. The company's focus on novel antigen targets positions it to address unmet needs in oncology, with this financing providing the necessary resources to pursue its ambitious growth strategy.
See full HOOKIPA Pharma company page
